In primary lymphoid endothelial cells, emtricitabine exposure produced measurable intracellular FTC-TP but ranked in the low-bioavailability tertile of the tested panel. The endpoint normalized intracellular triphosphate to extracellular parent drug; it was not an antiviral inhibition assay. [2]
Active-metabolite incorporation by HIV-1 reverse transcriptase
Biochemical assay · Purified recombinant HIV-1 RT; synthetic DNA–DNA primer–template [1]
The active triphosphate was incorporated during DNA-dependent synthesis. This endpoint measures enzyme kinetics, not parent-drug cellular potency.
Literature-Reported Treatment Conditions
- Treatment concentration
- Variable (−)FTC-TP concentrations; not a parent-drug dose
- Method
- Pre-steady-state rapid-quench incorporation analysis at 37°C
- Reported limits
- No single treatment concentration or fixed exposure duration applies; replicate count not specified for Table 3.
Methods and source locations
Compound reported in the paper: Emtricitabine 5′-triphosphate; Compound label in the paper: (−)FTC-TP
Mechanistic metabolite evidence; supplied parent emtricitabine was not assayed directly.
Table 3, DNA–DNA columns and footnotes; Materials and Methods: Reagents and rapid chemical quenching
DNA-dependent nucleotide incorporation: Transient kinetic analysis — Table 3: (−)FTC-TP row, DNA–DNA kpol; footnote a
DNA-dependent incorporation efficiency: Reported ratio of kinetic parameters — Table 3: (−)FTC-TP row, DNA–DNA kpol/Kd
Stereoselective incorporation by human mitochondrial polymerase γ
Biochemical assay · Recombinant human mitochondrial DNA polymerase γ holoenzyme; synthetic DNA–DNA substrate [1]
The (−) triphosphate was a much poorer substrate than the (+) enantiomer. Biochemical discrimination alone does not establish comparative clinical toxicity.
Literature-Reported Treatment Conditions
- Treatment concentration
- Variable triphosphate concentrations; Figure 3 spans 20–200 μM (−)FTC-TP
- Method
- Single-turnover incorporation kinetics at 37°C
- Reported limits
- No single fixed dose or exposure duration; Table 1 replicate count not specified.
Methods and source locations
Compound reported in the paper: Emtricitabine 5′-triphosphate; Compound label in the paper: (−)FTC-TP
Active-metabolite host-enzyme selectivity; no claim of zero mitochondrial toxicity.
Table 1 and footnotes; Results preceding Table 1; Figure 3; Methods: Reagents and rapid chemical quenching
Maximum observed (−)FTC-TP incorporation rate: Estimate from fastest observed incorporation rate — Table 1: (−)FTC-TP row; footnote a; Results preceding Table 1
Incorporation efficiencies of FTC enantiomers: Reported kinetic specificity constants — Table 1: FTC enantiomer rows
Emtricitabine metabolite accumulation in lymphoid endothelial cells
Cell-based study · Uninfected primary human lymph-node-derived lymphoid endothelial cells; four independent biological replicates [2]
FTC-TP accumulated in cells, but emtricitabine ranked in the low-bioavailability tertile of the tested panel. The ratio uses intracellular metabolite and extracellular parent drug.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2000 ng/mL emtricitabine
- Exposure duration
- 72 h
- Method
- Separate drug exposure; LC-MS/MS quantitation of cell-associated FTC-TP
- Reported limits
- Cell-treatment vehicle and detailed viability controls were not established from retrieved main text; supplement not retrieved.
Methods and source locations
Compound reported in the paper: Emtricitabine; Compound label in the paper: FTC; measured metabolite FTC-TP
Parent-drug uptake/metabolism model; no infection assay or antiviral potency endpoint.
Methods: ARVs, cell-associated quantitation, Sample size and Data analyses; Results: ARV bioavailability in HLECs; Figure 1
Intracellular FTC-TP normalized to extracellular FTC concentration: LC-MS/MS; ICC/Cmax ratio — Results: ARV bioavailability in HLECs; Figure 1b and caption